CymaBay Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, CBAY, CymaBay Therapeutics Inc, priceseries

CymaBay Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.14
Close
3.15
High
3.25
Low
3.08
Previous Close
3.13
Daily Price Gain
0.02
YTD High
3.65
YTD High Date
Jan 4, 2022
YTD Low
2.67
YTD Low Date
Jan 28, 2022
YTD Price Change
-0.49
YTD Gain
-13.46%
52 Week High
5.18
52 Week High Date
Mar 11, 2021
52 Week Low
2.67
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-1.56
52 Week Gain
-33.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
1.90
Jan 12. 2017
2.02
7 Trading Days
6.58%
Link
LONG
Feb 7. 2017
2.05
Mar 21. 2017
3.97
29 Trading Days
93.65%
Link
LONG
May 24. 2017
3.96
Jun 6. 2017
4.37
8 Trading Days
10.27%
Link
LONG
Jun 15. 2017
4.62
Jul 10. 2017
5.58
16 Trading Days
20.71%
Link
LONG
Sep 11. 2017
6.27
Oct 2. 2017
7.74
15 Trading Days
23.52%
Link
LONG
Dec 15. 2017
8.32
Jan 9. 2018
9.06
15 Trading Days
8.92%
Link
LONG
Jan 18. 2018
10.14
Feb 5. 2018
11.57
12 Trading Days
14.11%
Link
LONG
Feb 12. 2018
12.25
Mar 1. 2018
14.41
12 Trading Days
17.65%
Link
LONG
Jan 4. 2019
8.73
Jan 16. 2019
9.24
8 Trading Days
5.83%
Link
LONG
Feb 21. 2019
10.18
Mar 20. 2019
12.99
19 Trading Days
27.56%
Link
LONG
Mar 24. 2020
1.49
Mar 25. 2020
1.57
1 Trading Days
5.70%
Link
LONG
May 11. 2020
1.84
May 29. 2020
3.66
13 Trading Days
98.83%
Link
LONG
Aug 3. 2020
4.88
Aug 27. 2020
6.12
18 Trading Days
25.48%
Link
Company Information
Stock Symbol
CBAY
Exchange
NasdaqCM
Company URL
http://www.cymabay.com
Company Phone
510-293-8800
CEO
Sujal Shah
Headquarters
California
Business Address
7999 GATEWAY BLVD, SUITE 130, NEWARK, CA 94560
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001042074
About

CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate. MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Description

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading